Olga Löblová
Olga Löblová
Department of Sociology, University of Cambridge
Verified email at - Homepage
Cited by
Cited by
The implementation of managed entry agreements in Central and Eastern Europe: findings and implications
A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ...
Pharmacoeconomics 35, 1271-1285, 2017
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
L Gulácsi, AM Rotar, M Niewada, O Löblová, F Rencz, G Petrova, I Boncz, ...
The European journal of health economics 15, 13-25, 2014
Patients’ perceptions of information and education for renal replacement therapy: an independent survey by the European kidney Patients' Federation on information and support …
W Van Biesen, SN van der Veer, M Murphey, O Loblova, S Davies
PLoS One 9 (7), e103914, 2014
When epistemic communities fail: exploring the mechanism of policy influence
O Löblová
Policy studies journal 46 (1), 160-189, 2018
European integration in the era of permissive dissensus: Neofunctionalism and agenda-setting in European health technology assessment and communicable disease control
SL Greer, O Löblová
Comparative European Politics 15, 394-413, 2017
Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe
O Löblová
Health Economics, Policy and Law 11 (3), 253-273, 2016
Centralizing and decentralizing governance in the COVID-19 pandemic: The politics of credit and blame
SL Greer, S Rozenblum, M Falkenbach, O Löblová, H Jarman, N Williams, ...
Health Policy 126 (5), 408-417, 2022
Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries
AM Rotar, A Preda, O Löblová, V Benkovic, S Zawodnik, L Gulacsi, ...
Health Policy 122 (3), 230-236, 2018
When health technology assessment is confidential and experts have no power: the case of Hungary
M Csanádi, O Löblová, P Ozierański, A Harsányi, Z Kaló, M McKee, ...
Health Economics, Policy and Law 14 (2), 162-181, 2019
Epistemic communities and experts in health policy-making
O Löblová
European journal of public health 28 (suppl_3), 7-10, 2018
Half a century of Wilson & Jungner: reflections on the governance of population screening
S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ...
Wellcome Open Research 5, 2020
COVID-19 in Central and Eastern Europe: Focus on Czechia, Hungary, and Bulgaria
O Löblová, J Rone, E Borbáth
Coronavirus Politics: The Comparative Politics and Policy of COVID-19, 2021
The emerging social science literature on health technology assessment: a narrative review
O Löblová, T Trayanov, M Csanádi, P Ozierański
Value in Health 23 (1), 3-9, 2020
What has health technology assessment ever done for us?
O Löblová
Journal of health services research & policy 23 (2), 134-136, 2018
Transparency in practice: evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015
P Ozierański, O Löblová, N Nicholls, M Csanádi, Z Kaló, M McKee, L King
Health Economics, Policy and Law 14 (2), 182-204, 2019
Who’s afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic
O Löblová
Health Economics, Policy and Law 13 (2), 137-161, 2018
Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
O Löblová, M Csanádi, P Ozierański, Z Kaló, L King, M McKee
Health Policy 123 (7), 630-634, 2019
Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
O Löblová, M Csanádi, P Ozierański, Z Kaló, L King, M McKee
Health Policy 123 (8), 713-720, 2019
Coronavirus: what went wrong in the Czech Republic?
O Löblová
The Conversation 9, 2020
Shedding light on the HTA consultancy market: insights from Poland
M Csanádi, P Ozierański, O Löblová, L King, Z Kaló, L Botz
Health Policy 123 (12), 1237-1243, 2019
The system can't perform the operation now. Try again later.
Articles 1–20